Illumina plans to expand its sales presence both at home and abroad as decreasing prices for its microarray and sequencing products allow it to reach new customers, according to a company executive.

Christian Henry, general manager of Illumina's Genomics Solutions business, provided an update on the company at the RW Baird Growth Stock Conference, held last week in Chicago.

According to Henry, whose remarks were webcast, Illumina will "add significantly" to its sales force this year to reach customers in emerging markets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.